Aclaris Therapeutics Inc (NASDAQ:ACRS) has a beta value of 0.13 and has seen 0.62 million shares traded in the recent trading session. The company, currently valued at $176.30M, closed the recent trade at $2.14 per share which meant it gained $0.05 on the day or 2.39% during that session. The ACRS stock price is -166.36% off its 52-week high price of $5.70 and 72.43% above the 52-week low of $0.59. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.42 million shares traded. The 3-month trading volume is 489.64K shares.
The consensus among analysts is that Aclaris Therapeutics Inc (ACRS) is Buy stock at the moment, with a recommendation rating of 3.00. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aclaris Therapeutics Inc (NASDAQ:ACRS) trade information
Sporting 2.39% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ACRS stock price touched $2.14 or saw a rise of 0.93%. Year-to-date, Aclaris Therapeutics Inc shares have moved 103.81%, while the 5-day performance has seen it change 32.92%. Over the past 30 days, the shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) have changed 79.83%. Short interest in the company has seen 1.39 million shares shorted with days to cover at 5.23.
Wall Street analysts have a consensus price target for the stock at $25, which means that the shares’ value could jump 91.44% from the levels at last check today. The projected low price target is $25.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -1068.22% off the targeted high while a plunge would see the stock gain -1068.22% from the levels at last check today.
Aclaris Therapeutics Inc (ACRS) estimates and forecasts
Figures show that Aclaris Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 63.36% over the past 6 months, with this year growth rate of 58.06%, compared to 18.30% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 20.67% over the past 5 years.
ACRS Dividends
Aclaris Therapeutics Inc is expected to release its next earnings report on 2024-Nov-04 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Aclaris Therapeutics Inc (NASDAQ:ACRS)’s Major holders
Insiders own 2.65% of the company shares, while shares held by institutions stand at 76.15% with a share float percentage of 78.22%. Investors are also buoyed by the number of investors in a company, with Aclaris Therapeutics Inc having a total of 120.0 institutions that hold shares in the company. The top two institutional holders are BML CAPITAL MANAGEMENT, LLC with over 12.99 million shares worth more than $14.29 million. As of 2024-06-30, BML CAPITAL MANAGEMENT, LLC held 18.2739% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 4.69 million shares as of 2024-06-30. The firm’s total holdings are worth over $5.16 million and represent 6.5952% of shares outstanding.
